[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100512718":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":32,"collaborators":20,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":20,"enrollmentInfo":44,"targetDuration":20,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":20,"overallStatus":53,"whyStopped":20,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":20},{"fullName":5,"class":6},"University Health Network, Toronto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"high-grade epithelial ovarian cancers.","EXPERIMENTAL","individuals who have been diagnosed or are suspected to have high-grade serous ovarian cancers (HGSOC). They must have had a CT scan of their abdomen and pelvis within 6 weeks before enrolling in the study and be at clinical stage III or IV.",[13],"Radiation: FAPI PET CT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","FAPI PET CT","the utilization of Gallium 68 labelled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET\u002FCT to accurately stage high-grade epithelial ovarian cancers.",[9],null,[22,28],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Ur Metser, MD,FRCPC","CONTACT","416-946-4501","4394","ur.metser@uhn.ca",{"name":29,"role":24,"phone":25,"phoneExt":30,"email":31},"Ferdous Parveen, MBBS,CCRP","3329","ferdous.parveen@uhn.ca",{"type":33,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100512718","68ga-fapi-petct-in-the-staging-of-high-grade-epithelial-ovarian-cancers-a-pilot-study-100512718",false,"NCT05956093","68Ga-FAPI PET\u002FCT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study","FAST HOC-FAPI PET for Staging of High-Grade Serous Ovarian Cancer .","FAST HOC","Inclusion Criteria:\n\n* Patients will be eligible for inclusion in this study if they meet the following criteria:\n\n  * Age ≥18 years.\n  * Cytological or histological diagnosis of HGSOC, or clinical suspicion of HGSOC based on symptoms, physical exam, tumour markers, and imaging findings.\n  * Clinical stage III or IV, being considered for PCS or NACT.\n  * Contrast-enhanced CT abdomen and pelvis within 6 weeks of PET (prior to enrolment).\n\nExclusion Criteria:\n\nPatients will be ineligible to participate in this study if they meet any of the following criteria:\n\n* Inability to provide informed consent.\n* Contraindications for PET examination as per institutional safety guidelines, including but not limited to pregnancy, or inability to lie still for PET examination.\n* Evidence of the following epithelial ovarian cancer histological subtypes: Mucinous, low-grade serous, low-grade endometrioid, and low-malignant potential tumours.\n* Non-ovarian advanced gynecological malignancy","FEMALE","18 Years",{"count":45,"type":46},30,"ESTIMATED","INTERVENTIONAL",[49],"NA","The investigator will use a technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data are gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.\n\nThe purpose of this study is to find out if the use of 68Ga-PNT6555 (FAPI) PET-CT will improve the assessment of disease extent as compared to routine CT scans.",[52],"High Grade Serous Ovarian Cancer (HGSOC)","NOT_YET_RECRUITING","2025-08-14",{"date":56,"type":57},"2025-08-15","ACTUAL",{"date":59,"type":46},"2025-09-25",{"date":61,"type":46},"2026-05-30",{"name":5,"class":6}]